Long-term oncological outcomes of ovarian serous carcinomas with psammoma bodies: a novel insight into the molecular pathogenesis of ovarian epithelial carcinoma.
A two-tier system in which ovarian epithelial carcinomas are subdivided into type I and type II tumors has been proposed on the basis of recent molecular pathogenesis findings. Type I tumors, unrelated to tumor protein p53 (TP53) mutations, show favorable prognosis in a slow step-wise process, whereas type II tumors, related to TP53 mutations, contribute to poor prognosis. Ovarian serous carcinomas with excessive psammoma bodies behave like type I tumors. However, their etiology and prognostic significance remain obscure. The objective of the present study was to evaluate the characteristic features and potential relevance of psammoma bodies to the clinical outcome of 44 patients with serous carcinomas with long-term follow-up. The 5- and 10-year survival rates were significantly different between the serous carcinomas with less than 5% area of psammoma bodies and those at least 5% area (P < 0.01). All tumors with at least 5% area were both diploid and immunohistochemically negative for TP53 mutations. All patients with these tumors, including eight with International Federation of Gynecology and Obstetrics (FIGO) stages III or IV disease, survived more than 5 years and their 10-year survival rate was 76%. In multivariate analysis using clinical parameters, the apparent existence of psammoma bodies was an indication to view serous carcinomas as type I tumors with long-term survival. Our results suggested that the formation of psammoma bodies is associated with increased apoptotic tumor cell death related to normal TP53 function. The pathological findings of psammoma bodies might contribute to the consideration of pathogenesis and to the development of prognostic prediction rules for serous carcinomas.
Motohara
Takeshi
T
Department of Gynecology and Reproductive Medicine and Surgery, Kumamoto University, Kumamoto City, Japan.
Tashiro
Hironori
H
Miyahara
Yo
Y
Sakaguchi
Isao
I
Ohtake
Hideyuki
H
Katabuchi
Hidetaka
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018284:Cystadenocarcinoma, Serous / Q000209:etiology / Q000401:mortality / Q000473:pathology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000209:etiology / Q000401:mortality / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000209:etiology / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D015996:Survival Rate
Am J Pathol. 2004 May;164(5):1511-8
15111296
Blood. 1993 Mar 15;81(6):1607-13
7680921
Jpn J Cancer Res. 1992 Sep;83(9):978-84
1429209
Gynecol Oncol. 1983 Jun;15(3):370-80
6862292
Gynecol Oncol. 2001 Apr;81(1):10-7
11277643
Int J Gynaecol Obstet. 2003 Oct;83 Suppl 1:135-66
14763172
Cancer. 1988 Nov 15;62(10):2212-22
3179935
Scanning Microsc. 1995;9(4):1137-75; discussion 1175-8
8819895
Pathol Int. 2000 Jul;50(7):531-5
10886734
Cancer. 1977 Jun;39(6):2451-9
872045
Adv Cancer Res. 2001;82:55-84
11447765
Eur J Gynaecol Oncol. 1988;9(3):234-41
3391195
Br J Cancer. 1972 Aug;26(4):239-57
4561027
Exp Cell Res. 1996 Aug 1;226(2):387-97
8806443
J Clin Oncol. 1988 Feb;6(2):282-90
3276825
Int J Gynaecol Obstet. 2005 Mar;88(3):286-91
15733883
Br J Cancer. 2005 Jul 11;93(1):116-23
15956975
Int J Clin Oncol. 2001 Aug;6(4):177-82
11706555
Gynecol Oncol. 1982 Aug;14(1):6-14
7095589
Int J Gynecol Pathol. 1990;9(2):110-21
2332269
Cancer Sci. 2003 Nov;94(11):953-9
14611671
Int Rev Cytol. 1980;68:251-306
7014501
Am J Surg Pathol. 2004 Apr;28(4):496-504
15087669
J Pathol. 2004 Mar;202(3):336-40
14991899
Int J Gynecol Pathol. 1998 Jan;17(1):54-60
9475193
Am J Surg Pathol. 1998 Jul;22(7):849-62
9669347
Gynecol Oncol. 1992 Nov;47(2):159-66
1468693
Obstet Gynecol. 1982 May;59(5):576-82
7070728
Am J Obstet Gynecol. 1971 Jan 1;109(1):113-8
4321483
Eur J Cancer Clin Oncol. 1989 Apr;25(4):711-20
2714347
Am J Pathol. 1997 Jan;150(1):177-85
9006334
Cancer. 1972 May;29(5):1326-35
5021621
Cancer. 1992 Jun 1;69(11):2668-75
1571896
Acta Pathol Microbiol Scand. 1965;:Suppl 176:1-90
5837391
Arch Gynecol Obstet. 1990;247(3):125-9
2369150
Int Rev Cytol. 2005;242:1-54
15598466
Carcinogenesis. 2009 Mar;30(3):423-31
19126650
Cancer Res. 1996 May 1;56(9):2178-84
8616869
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
17237035
Anticancer Res. 2001 May-Jun;21(3B):1723-30
11497252